Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.
Chandra Mohan, MD, PhD, provided an update on the immunology behind SLE and research findings from the past decade.
ACR CONVERGENCE 2020—Eric Rubin, MD, PhD, took over as editor in chief of the New England Journal of Medicine in September 2019, just a few months before COVID-19 began taking over the world. Since then, Dr. Rubin’s perspective on the pandemic has been unlike that of any other person: He has led reviews of a…
Three doctors reported on advances in research & treatments for lupus nephritis.
Despite high voter turnout and many new faces entering Congress, minimal power shifts in most levels of government will have implications for the ACR’s advocacy agenda in 2021.
To her new role as ACR Secretary, Dr. Desir brings extensive experience in both private practice and academic medicine, more than a decade of volunteer leadership experience in the ACR and a deep commitment to service.
At the American Medical Association House of Delegates Special Meeting held Nov. 13–17, 2020, the ACR’s delegation successfully led an effort to update AMA policies on home infusion and copay accumulators.
ACR CONVERGENCE 2020—Rheumatologists and patients have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), but a better understanding of the underlying mechanisms behind the disease helps shed light on potential treatments. That was the theme of the ACR Convergence session State of the Art: Lupus—The Future Is Now, led by Peggy…
ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke…
After ACR and other provider and patient organizations expressed concerns about a proposed copay accumulator policy set to take effect Jan. 1, 2021, UnitedHealthcare has indefinitely delayed its implementation but is continuing to explore options to reduce spending on specialty drugs.